Corient Private Wealth LLC Grows Stake in Glaukos Corporation $GKOS

Corient Private Wealth LLC grew its stake in shares of Glaukos Corporation (NYSE:GKOS) by 999.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 30,978 shares of the medical instruments supplier’s stock after acquiring an additional 28,160 shares during the period. Corient Private Wealth LLC’s holdings in Glaukos were worth $3,498,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its position in Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 122 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares in the last quarter. CWM LLC lifted its stake in shares of Glaukos by 25.2% in the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Glaukos by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after buying an additional 144 shares during the last quarter. Finally, Evergreen Capital Management LLC grew its holdings in shares of Glaukos by 4.3% during the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GKOS. BTIG Research reissued a “buy” rating and set a $162.00 price target on shares of Glaukos in a research report on Wednesday, June 10th. Citigroup increased their target price on Glaukos from $140.00 to $162.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. William Blair reissued an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday, April 30th. Finally, Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a research note on Sunday, June 21st. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $149.17.

Insider Transactions at Glaukos

In other news, Director Leana Wen sold 1,700 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.35, for a total value of $243,695.00. Following the transaction, the director directly owned 19,739 shares in the company, valued at $2,829,585.65. This trade represents a 7.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the sale, the director directly owned 35,528 shares of the company’s stock, valued at $5,000,921.28. The trade was a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 41,273 shares of company stock valued at $5,832,003 over the last 90 days. 5.90% of the stock is owned by corporate insiders.

Glaukos Stock Up 1.3%

GKOS opened at $144.37 on Friday. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average price of $127.29 and a 200-day moving average price of $118.14. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $148.11. The stock has a market capitalization of $8.48 billion, a price-to-earnings ratio of -44.02 and a beta of 0.82.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 41.2% compared to the same quarter last year. Equities research analysts forecast that Glaukos Corporation will post -0.57 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.